Dupilumab for the Treatment of Chronic Inducible Cold Urticaria in Patients Who Remain Symptomatic Despite the Use of H1-antihistamine (LIBERTY-CINDU CUrIADS)

Inclusion Criteria: * Participant had to be ≥12 years to 80 years of age inclusive at the time of signing the informed consent * Participants who had a diagnosis of primary acquired chronic inducible ColdU defined as recurrence of itchy wheals and/or angioedema due to cold for longer than 6 weeks prior to screening visit (Visit 1) * Participants with positive ice cube provocation test, ie, presenting at least a confluent hive/wheal on the exposed skin area, at the screening visit (Visit 1) and randomization visit (Visit 2) * Participants meeting at least 1 of the following criteria despite regular/daily or as needed use of H1-antihistamine (AH): * Urticaria Control Test (UCT) (4 item) \<12 at the screening visit (Visit 1) and randomization visit (Visit 2) * Within 6 months prior to the screening visit, documented medical history of cold exposure triggered anaphylaxis or oropharyngeal edema * Within 6 months prior to the screening visit, documented medical history of cold exposure triggered urticaria requiring emergency medical care visit or treatment with epinephrine * Participants using a study defined H1-antihistamine regularly/daily or as needed for primary acquired chronic inducible cold urticaria * Body weight ≥30 kg Exclusion Criteria: Participants were excluded from the study if any of the following criteria applied: * Clearly defined underlying etiology for urticaria other than primary acquired chronic inducible ColdU * Presence of skin morbidities other th…